Rost-9D/iStock via Getty ImagesAllogene Therapeutics, Inc. (NASDAQ:ALLO) is a clinical-stage biotech company developing allogeneic chimeric antigen receptor T cell (AlloCAR T) therapies for cancer and autoimmune diseases. ALLO uses advanced gene-editing platforms like TALEN and CRISPR/Cas9 to engineer donor-derived T cells. These off-the-shelf treatments overcome the limitations of autologous therapies by targeting and killing malignant cells. The company’s robust pipeline covers hematologic malignancie ...